Innovative OSA Screening in Head and Neck Cancer Patients With the Apneal App

Launched by UNIVERSITY HOSPITAL, CAEN · Mar 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new smartphone app called Apneal, designed to help diagnose obstructive sleep apnea syndrome (OSA) in patients who have head and neck lesions, which may be cancerous. OSA is a condition that causes breathing problems during sleep, leading to issues like fatigue and increased risk of heart problems. The goal of the trial is to see if this app can be an effective and easy way to diagnose sleep apnea and monitor its progress during treatment.

To participate in this study, you need to be an adult undergoing tests for a suspected head and neck cancer and have confirmed that the lesion is malignant. Participants will complete a short consultation, answer some questions, and then wear the smartphone overnight to collect sleep data. This will happen at the start of your care and again six months later. If the results are unclear, an additional test may be needed. The trial is not yet recruiting participants, but it aims to provide better, more accessible screening for sleep apnea, ultimately helping improve patients' quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients undergoing diagnostic workup for a lesion suspected to be a head and neck cancer, followed by confirmation of the malignant nature of the lesion. The following locations will be included: the nasopharynx, nasal cavities, sinuses, oral cavity, oropharynx, hypopharynx, larynx, and parotid gland.
• • The collection of the informed consent signature is required.
• • The patient must be affiliated with the social security system.
• Exclusion Criteria:
• • Minor patients, or those under judicial protection, guardianship, or curators.
• • Lack of confirmation of the malignant nature of the lesion.
• • Diagnosis of metastatic cancer.
• • Known history of obstructive sleep apnea syndrome (OSAS) or previously treated head and neck cancer.